Astra S DR MRI IPG; Astra S SR MRI IPG; Astra XT DR MRI IPG; Astra XT SR MRI IPG; Azure S DR MRI IPG; Azure S SR MRI IPG
Medtronic, Inc. · Decision date Oct 29, 2026
What did the FDA decide?
The FDA recorded decision OK30 on 2026-10-29 for PMA supplement P980035/S849, submitted by Medtronic, Inc. as a 30-Day Notice. The supplement covers a series of battery electrolyte fill manufacturing process updates at Medtronic Energy and Components Center, filed under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The affected devices are the Astra S DR, Astra S SR, Astra XT DR, Astra XT SR, Azure S DR and Azure S SR MRI implantable pulse generators, classified as permanent implantable pulse generators (product code NVZ) in the cardiovascular specialty.
The supplement modifies a manufacturing step for the battery component rather than the pulse generator system as a whole, and the record does not establish a new approval of the complete device. The source data do not include the supplement documents, the specific electrolyte formulation or fill parameters changed, any performance testing, or the basis for the OK30 decision. Whether the updated process affects battery behavior in clinical use is not addressed in the available record.
Readers should treat this as a dated administrative record of a process change and not as evidence of changed clinical performance or labeling.
FDA approval order statement
a series of battery electrolyte fill manufacturing process updates at Medtronic Energy and Components Center
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 29, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P980035/S849
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- NVZ
- Decision code
- OK30
- Decision date
- Oct 29, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Pulse generator, permanent, implantable.
- Applicant
- Medtronic, Inc.
- Product code
- NVZ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P980035. Subsequent supplements may change the device or its indications.
FDA decision timeline
P980035 · Original PMA
MEDTRONIC KAPPA 700/600 SERIES PULSE GENERATORS AND MODEL 9953 SOFTWARE
P980035/S847 · Related supplement
Astra S DR MRI IPG, Astra S SR MRI IPG, Astra XT SR MRI IPG, Azure S DR MRI IPG, Azure S SR MRI IPG, Azure XT DR MRI IPG
P980035/S849 received
Application receipt date recorded by FDA.
P980035/S848 · Related supplement
Astra S DR MRI IPG (X3DR01); Astra S SR MRI IPG (X3SR01); Astra XT DR MRI IPG (X1DR01); Astra XT SR MRI IPG (X1SR01); Az
P980035/S849 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P980035. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P980035
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA approval | Jan 29, 1999 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 5, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St. N.E, Ms Mvs11, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P980035/S849
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

